This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riad, A. Articles by Tschöpe, C. Search for Related Content PubMed PubMed Citation Articles by Riad, A. Articles by Tschöpe, C. Related Collections Preclinical Intervention Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms

Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice

¹ Charite-Universitätsmedizin Berlin, Campus Benjamin Franklin, Med. Klinik II, Department of Cardiology and Pulmology, Hindenburgdamm 30, Berlin, Germany; ² University of Greifswald, Depatment of Pharmacology, Friedrich-Loeffler-Str. 23d, Greifswald, Germany; and ³ University of Zürich, UniversitätsSpital Zürich, Herz Kreislauf Zentrum, Kardiologie, Rämistrasse 100, Zürich, Suisse

Requests for reprints: Carsten Tschope, Charite - Universitätsmedizin Berlin, Campus Benjamin Franklin, Med. Klinik II, Department of Cardiology and Pulmology, Hindenburgdamm 30, 12203 Berlin, Germany.

Key Words: doxorubicin • cardiotoxicity • statins

Cardiotoxicity, which may result from intense cardiac oxidative stress and inflammation, is the main limiting factor of the anticancer therapy using doxorubicin. Because statins might exert beneficial pleiotropic cardiovascular effects, among other things, by anti-inflammatory and antioxidative mechanisms, we investigated whether or not fluvastatin pretreatment can attenuate doxorubicin-induced cardiotoxicity. Five days after a single injection of doxorubicin (20 mg/kg; i.p.), left ventricular (LV) function was measured in fluvastatin-treated (DoxStatin; 100 mg/kg/day, p.o.) and saline-treated (doxorubicin) mice (n = 8 per group) by a micro conductance catheter. Untreated mice served as controls (placebo; n = 8 per group). After measurement of cardiac function, LV tissues were analyzed by molecular biological and immunohistologic methods. Injection resulted in significantly impaired LV function (LV pressure, –29%; dp/dtmax, –45%; cardiac output, –68%; P < 0.05) when compared with placebo. This was associated with a significant increase in cardiac oxidative stress, inflammation and apoptotic mechanisms, as indicated by significant increased cardiac lipid peroxidation activity, protein expression of nitrotyrosine, tumor necrosis factor and Bax (P < 0.05). In contrast, DoxStatin mice showed improved LV function (LV pressure, +24%; dp/dtmax, +87%; cardiac output, +87%; P < 0.05) when compared with untreated doxorubicin mice. This was associated with reduced cardiac expression of nitrotyrosine, enhanced expression of the mitochondrial located antioxidative SOD 2, attenuated mitochondrial apoptotic pathways, and reduced cardiac inflammatory response. Statin pretreatment attenuates doxorubicin-induced cardiotoxicity via antioxidative and anti-inflammatory effects. [Cancer Res 2009;69(2):695–9]

This article has been cited by other articles:

				P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, L. Liaudet, C. Szabo, and P. Pacher Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1466 - H1483. [Abstract] [Full Text] [PDF]